NOT YET RECRUITING
NCT07951060
LP-184 for Advanced or Metastatic Urothelial Carcinoma Selected by PTGR1 Expression and DNA Repair Deficiency
This study investigates the safety and potential antitumor activity of LP-184 in patients with advanced or metastatic urothelial carcinoma.
LP-184 is an investigational anticancer drug designed to damage the DNA of cancer cells. Certain cancer cells may be particularly sensitive to LP-184 if they have impaired DNA repair mechanisms and express a protein called PTGR1, which is involved in activating the drug.
The study aims to investigate whether LP-184 can be safely administered and whether it can reduce tumor growth in patients whose tumors have these specific characteristics.
The study consists of two parts. Phase Ib will evaluate the safety and tolerability of LP-184 and determine the recommended dose for Phase II. Phase II will investigate the antitumor activity of LP-184 by assessing tumor response to treatment.
All participants will receive LP-184 intravenously on days 1 and 8 of each 21-day treatment cycle. Up to 39 patients will be enrolled in the study.
Gender: All
Ages: 18 Years - Any
Advanced Urothelial Carcinoma
Urothelial Carcinoma (UC)
Urothelial Cancer of Renal Pelvis
+6